After Britain’s approval of Merck’s anti-Covid drug, Pfizer reveals the results of its Coronavirus pill
The company announced today that its new oral antiviral candidate against Covid-19, Paxlovid, significantly reduces the risk of hospitalization or death by up to 89%.
The data came from a randomized, double-blind study of 1,219 non-hospitalized adult patients with Covid-19 at high risk of progressing to serious illness.
The patients came from clinical trial centers in North and South America, Europe, Africa, and Asia, with 45% from the US.
In detail, the analysis showed an 89% reduction in the risk of Covid-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint) .
0.8% of patients who received the Pfizer drug were hospitalized until day 28 after randomization (3/389 hospitalized with no deaths), compared to 7.0% of patients who received placebo and were hospitalized or died (27 / 385 hospitalized with 7 subsequent deaths).
Pfizer Anti-Covid Pill: Similar reductions in Covid-19-related hospitalization or death seen in patients treated within five days of symptom onset
0% of patients who received Paxlovid were hospitalized until day 28 after randomization (6/607 hospitalized, no deaths), compared to 6.7% of patients who received a placebo (41/612 hospitalized with 10 deaths later), with high statistical significance. .
In the general study population through day 28, no deaths were reported in patients receiving Paxlovid compared to 10 (1.6%) deaths in patients receiving placebo.
Pfizer President and CEO Albert Bourla said: “Today’s news is a true turning point in global efforts to stem the devastation of this pandemic.
These data suggest that our oral antiviral candidate, if approved or licensed by regulators, has the potential to save patients’ lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of ten hospitalizations, “he concluded.